Conjugated estrogens/bazedoxifene - Ligand Pharmaceuticals/Pfizer
Alternative Names: Aprela; Bazedoxifene acetate/conjugated estrogens; Bazedoxifene/conjugated estrogens; Bazedoxifene/Premarin®; BZA/CE; CE/BZA; Conjugated estrogens/bazedoxifene acetate; Duavee; Duavive; Premarin®/bazedoxifene; SERM + PremarinLatest Information Update: 05 Nov 2023
At a glance
- Originator Ligand Pharmaceuticals; Wyeth
- Developer Merck Sharp & Dohme; National Cancer Institute (USA); Northwestern University; Pfizer
- Class Azepines; Calcium regulators; Estradiol congeners; Hormonal replacements; Indoles; Osteoporosis therapies; Phenols; Small molecules
- Mechanism of Action Estrogen receptor agonists; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Atrophic vaginitis; Postmenopausal osteoporosis; Vasomotor symptoms
- Phase II Breast cancer
Most Recent Events
- 22 Jul 2019 Conjugated estrogens/bazedoxifene is not yet available for Postmenopausal osteoporosis in Chile (PO)
- 22 Jul 2019 Conjugated estrogens/bazedoxifene is not yet available for Vasomotor symptoms in Chile, Canada (PO)
- 04 Feb 2019 Chemical structure information added